Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
BT-11 significantly decreases interferon gamma positive (IFNγ+) and tumor necrosis factor alpha positive (TNFα+) cluster of differentiation 4 positive (CD4+) T cells and increases forkhead box P3 positive (FOXP3+) CD4+ T cells in colonic lamina propria mononuclear cells from patients with CD and patients with UC at concentrations of 0.01 µM when treated ex vivo.
|
31077582 |
2020 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The activation of A3AR by 2-Cl-IB-MECA significantly decreased TNF-α and IL-1β production and attenuated the NF-κB p65 activation in colonic tissues from patients with UC.
|
31714673 |
2020 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Treatment with tumor necrosis factor antagonists increased steadily for patients with CD (43.4% of all patients in Brazil were treated in 2014) but less so for patients with UC (4.5% of all patients were treated in 2014).Surgery for IBD decreased with time.
|
31252191 |
2020 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor.
|
31628842 |
2020 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
To date, responsiveness to tumor necrosis factor alpha inhibitors in ulcerative colitis (UC) patients is not predictable.
|
31782956 |
2020 |
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Finally, colonic IL-8+ T cells co-expressed GM-CSF, TNF- and IL-6 were detected ex vivo and, promoted by IL-12 in the mucosa and mLNs in UC only.
|
31206576 |
2020 |
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis.
|
31790426 |
2019 |
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Compared with that in the DSS group, FMT ameliorated the severity of inflammation due to ulcerative colitis in mice, which was accompanied by a significantly decreased MPO activity, reduced levels of TNF-α and IL-1β, and an increased level of IL-10 in colon tissue (all P<0.05).
|
30906449 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Expression levels of IgA and sIgA decreased, while IL-6, IL-8 and TNF-α further increased in the stress-treated UC mice (P<0.05).
|
30783488 |
2019 |
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This is the first time that the effect of original CS against UC in mice has been reported and it is through promoting dominant intestinal microflora such as <i>Blautia</i>, mitigating intestinal microflora dysbiosis, and regulating the expressions of TNF-α, claudin-1, occludin, and ZO-1.
|
31731793 |
2019 |
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We aimed to investigate the impact of the single nucleotide polymorphisms of rs34436714 of the NOD-like receptor protein 12 gene on the production of tumor necrosis factor-alpha (TNFα) in patients with inflammatory bowel disease (IBD)In a matched case-control study 90 patients with IBD, 56 with Crohn disease (CD) and 34 with ulcerative colitis, were genotyped and compared to 98 healthy comparators matched for age and gender.
|
31169706 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients.
|
30544140 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rates of anti-TNF therapy during emergency admission for UC have increased whereas overall colectomy rates have fallen.
|
31714573 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The levels of LMR, endotoxin, and TNF-α were higher in the UC group than in the CD group, but 25(OH)D was lower (p<0.05).
|
30429108 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Baicalin significantly increased the activity of SOD, CAT and GSH-Px in colon tissue of rats with UC, but significantly decreased the content of MDA, IL-1β, MPO, PEG2 and TNF-α in colon tissue of rats with UC.
|
31103874 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Aberrant activation of the immune response to resident microflora contributes to overproduction of TNF-α in the mucosal tissue of the gastrointestinal tract; a hallmark of UC.
|
30615542 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The cytokine TNF is thought to play a major role in the immunopathogenesis of ulcerative colitis, and anti-TNF antibodies are considered as cornerstones of clinical therapy.
|
31747580 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
In patients with UC (overall or naive to TNF antagonist therapy), a significantly greater percentage of patients given vedolizumab achieved the predefined composite symptom score at weeks 2, 4, and 6 compared to those given placebo.
|
29857145 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Baseline whole blood TREM1 was downregulated in future anti-TNF responders, both in UC (FC = 0.53, p = .001) and CD (FC = 0.66, p = .007), as well as in the complete cohort (FC = 0.67, p < .001).
|
30685385 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
To examine whether there is an increased risk of developing Crohn's disease (CD) and ulcerative colitis (UC) while under treatment with anti-TNFα agents for diseases other than inflammatory bowel disease (IBD) METHODS: A nationwide cohort study, based on Danish health registries, of all patients who utilised anti-TNFα agents for non-IBD indications.
|
31267570 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Two main points may help physicians to decide when the surgical option may be considered in patients with chronic refractory UC: (1) a first risk stratification can be obtained by analyzing factors at baseline and medical history, including the previous exposure to anti-TNFs; (2) during therapy with biologics, the early assessment (after 12-16 weeks of treatment) of clinical and endoscopic response is a strong predictor of the subsequent risk of colectomy.
|
30826279 |
2019 |
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The levels of IL-6 and TNF-α in peripheral blood in the UC patient group were significantly increased compared with those in the healthy adult group (P<0.01), while the levels of IL-10 and IL-4 in peripheral blood were significantly decreased compared with those in the healthy adult group (P<0.01).
|
30906432 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present study aimed to develop a tumor necrosis factor‑α (TNF‑α) B‑cell epitope/IL‑1β helper T lymphocyte epitope complex MAP vaccine for the alleviation of ulcerative colitis (UC) in mice.
|
31524230 |
2019 |
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
It is found that the anti-UC activities are mainly focused on targeting inflammation or oxidative stress, which is associated with increasing the levels of anti-inflammatory cytokine (IL-4, IL-10, SOD), suppressing the levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8, IL-23, NF-κB, NO), reducing the activity of MPO, MDA, IFN-γ, and iNOS.
|
30797423 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
We collected information on 39 patients with an active steroid-refractory UC (31 with active severe UC and 36 failed by treatment with a tumor necrosis factor antagonist) who received a calcineurin inhibitor as induction therapy along with vedolizumab as maintenance therapy.
|
30213584 |
2019 |